6^th European Conference on Predictive , Preventive and Personalized Medicine & Molecular Diagnostics September 14-15, 2017 Edinburgh, Scotland

Biography:

Silvia Binder, ND PhD is the CEO of the Ondamed Companies and the Founder of The Binder Institute for Personalized Medicine in Southern Germany where she helps chronically ill patients from around the world. She was born in Germany, grew up in Vienna, Austria, and lived in New York for 20 years. Dr. Binder lectures around the globe, offers Courses on Bio-IT Integrative Personalized Medicine, is faculty of the American Academy for Anti-Aging Medicine and serves on several medical Advisory Boards in North America. She is the author of various scientific papers and the book “ONDAMED A story of love, healing, and medical revolution

Abstract:

The realm of personalized Bio-IT is increasingly in demand by physicians/therapists and patients alike. Its foundation is as old as human history and with today’s science and technology it is an available modality to integrate into any type of practice. Working with the energy of a human’s body is a standard in diagnostics of all types of medical specialties. Diagnostically we measure pathology with technologies like MRI, EKG, EEG, Ultrasound, Thermography, and more. On the therapeutic side, the use of physics or energetics in combination with the chemistry model is still a blank area to many physicians due to the lack of information during their primary education. The advanced physician/therapist is seeking the missing link to the chemistry model which is discussed here. The global trend proves patients are not only seeking but demanding less chemical and non-invasive solutions for their chronic illnesses. Moreover, patients are seeking physicians/therapists who recognize their personal needs and are able to offer personalized therapy solutions for getting and staying well

Biography:

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology. In 2001, Suchkov maintained his Doctor Degree at the National Institute of Immunology, Russia.From 1989 through 1995, Dr Suchkov was being a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004 - a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI). In 1993-1996, Dr Suchkov was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.At present, is Prof Sergey Suchkov, MD, PhD , I.M.Sechenov First Moscow State Medical University, Moscow Engineering Physical Institute (MIFI)

Abstract:

Abs against myelin basic protein (MBP), cardiac myosine (CM) and thyroid Ags (TPO, T3 and T4) endowing with proteolytic activity (Ab-proteases) are of great value to monitor chronic autoimmune inflammation and to thus illustrate the evolution of either of the above-mentioned autoimmune disorders. Ab-proteases from MS, AIM and AIT patients exhibited specific proteolytic cleavage of MBP, CM and thyroid Ags (T3, T3, TPO), respectively The activity of the Ab-proteases markedly differs between: (i) the patients and healthy controls, and (ii) different clinical courses, to to predict transformation prior to changes of the clinical course.

The activity of Ab-proteases was first registered at the subclinical stages 1-5 years (regardless to type of the disorder) prior to the clinical illness. Some (12-24%) of the direct disease-related relatives are seropositive for low-active Ab-proteases from which seropositive relatives established were being monitored for 2-3 years whilst demonstrating a stable growth of the Ab-associated proteolytic activity. We saw also low-active Ab-proteases in persons at MS-, AIM- and AIT-related risks (at the subclinical stages), and primary clinical, ultrasonic and MRT manifestations observed were coincided with the activity to have its mid-level reached. The activity of Ab-proteases would confirm a high subclinical and predictive value of the translational tools as applicable for personalized monitoring protocols. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism. Of tremendous value are Ab-proteases directly affecting the physiologic remodeling of tissues with multilevel architecture. Further studies on targeted Ab-mediated proteolysis may provide a supplementary tool for predicting exacerbations and thus the disability of the MS, AIM and AIT patients.

Biography:

Mr. Malakoudis Eleftherios is a Greek citizen who has finished the bachelor studies of Medical Faculty of Novisad, Vojvodina, Yugoslavia in 1995. After the studies he entered the field of Medical Devices and rapidly reached senior managing positions. Soon enough he founded ALVEK Medical Implants, a company which is among the top 50 European companies of this field. Among others, currently he is holding the General Director’s position at MEDFIT Hellas (www.medfit.gr). His constant will for unification of the Markets in Balkan and Eastern European Countries and of course his scientific background nominates him as an active and really effective corporate entity in this part of the world

Abstract:

Genomics in the prediction of adverse cardiac events is strongly demonstrated in the literature. Stent thrombosis, in-stent restenosis and dual antiplatelet therapy tolerance seem to be the fields of the early prediction of relevant dependence of the human genomic status. Coronary angioplasty is the interventional approach of the inner lumen of the coronary arteries after a severe thrombus blockage. An intraluminal prothesis is advanced percutaneously through a wire to the target vessel and after a successful expansion is restoring the physiological anatomy of the lumen maintaining the proper blood flow.

The European Guidelines are suggesting Dual AntiPlatelet Therapy (DAPT) from 6 to 12 months. Despite of the effectiveness of the DAPT to avoid thrombus formation, one limitation is severe bleeding and of course patients with stent thrombosis (ST).

The second limitation is in-stent restenosis (ISR). In-stent restenosis is the phenomenon of the reclosure of the stent implants in the target vessel after a successful angioplasty.The last projected topic about the prediction of an adverse cardiac event is to improve coronary heart disease through genetic profiling.

1.CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case– control study. (by A. Harmsze et al., doi:10.1093/eurheartj/ehq321) This case–control study aimed to determine the influence of genetic variations related to the pharmacokinetics and pharmacodynamics of clopidogrel on the occurrence of ST in patients who were on clopidogrel and aspirin treatment at the time of the event. The conclusion is that carriers of the CYP2C19*2 and CYP2C9*3 loss-of-function alleles were at a 1.7- and 2.4-fold increased risk of developing ST, respectively. The influence of these genetic variants was most profound on the risk of subacute ST. Personalized therapy targeting patients who carry these genetic variants might help to improve the clinical outcome after stent implantation.

2.The Cardio Gene Study: genomics of in-stent restenosis. The Cardio Gene Study is designed to understand ISR. Global gene and protein expression profiling define molecular phenotypes of patients. Well-defined clinical phenotypes will be paired with genomic data to define analyses aimed to achieve several goals. These include determining blood gene and protein expression in patients with ISR, investigating the genetic basis of ISR, developing predictive gene and protein biomarkers, and the identification of new targets for treatment.

Genomics in Action: Seeking To Improve Coronary Stent Therapy Through Genetic Profiling (Elizabeth G. Nabel, M.D.) Coronary heart disease is the leading cause of death in the United States and other industrialized countries. To improve the outlook for the 13 million Americans suffering from this common disorder, a laboratory that recently joined the National Human Genome Research Institute (NHGRI) is tapping into the power of genomics to develop better therapies. Of course further investigation and larger trials have to be scheduled and the researchers have to focus on the personalization of the molecular and genomic level

Biography:

GalyaNaydenovaAtanasova completed her Ph.D. training in Cardiology from Department of Cardiology, Pulmonology and Endocrinology at Pleven Medical University, Bulgaria. She is an assistant prof. and cardiologist at the Department of Internal Medicine, Medical University, Pleven, Bulgaria. She specialized in General Medicine from Pleven Medical University, Bulgaria during 1993. She has attended to many International Events and presented her research work. She did many researches on metabolic syndrome and myocardial infarction of heart

Abstract:

In a number of epidemiological studies, elevated BP has been identified as a risk factor for coronary heart disease, heart failure, cerebrovascular disease, peripheral arterial disease, renal failure, and, more recently, atrial fibrillation.

The purpose of this study was to estimate the impact of the blood pressure on the prematurity of occurrence of myocardial infarction by logistic regression analysis.

During year 2012 study in 99 subjects with survived MI, inhabitants of Pleven region in Republic of Bulgaria was conducted.
The following biomarkers are tested (fasting): HDL-cholesterol, serum triglycerides (TG) and total cholesterol (TC). Data processing is a logistic regression analysis.

In our study developed two regression models. The first model includes DBP, level of Tg and TC level. The impact of the increase in DBP by 10% on average OR was significantly less in women than in men. The second model includes DBP, Tg levels and levels of HDL-cholesterol. With the greatest influence of DBP in men, where the OR increased 2.19 fold increase in DBP of 10% from the average, while the increase for women was almost twice less.

For men, the second level of influence risk factor is the DBP, and for women it is Tg. Third degree of risk factor for women is total cholesterol and in men at this level and the level of HDL-cholesterol have almost the same effect

Biography:

Okoli J. Bamidele is a native of Anambra, educated in the public schools of Ogun State, at Federal University of Agriculture Abeokuta (B.Sc. in Chemistry, 2001), Oyo State, at the famous University of Ibadan (M.Sc. in Organic Chemistry, 2005), and Kaduna State, at the great Ahmadu Bello University, Zaria  (Ph.D. in Organic Chemistry, 2015). Following his Masters at the University of Ibadan, he joined the Chemistry Department of Bingham University in 2006. Presently a Postdoctoral Research Fellow at the Institute of Chemical and Biotechnology, Vaal University of Technology, South Africa,

 Okoli has published over 16 research papers in isolation and characterization of organic compounds from native plants. He is the author of Organic Spectroscopy; a one-volume treatment designed for graduate students and advanced undergraduates.

Okoli is a member of America Chemical Society and recently joined Chemical Society of Nigeria. He was the Students Industrial Work Experience Scheme, Coordinator and Deputy, Coordinator, School of Basic Studies, Bingham University and an authorized representative of an African-Asian educational exchange program

Abstract:

Alepidea amatymbica, a herbaceous plant with a broad ethnomedicinal application among the native of Eastern and Southern Africa. The isolation of diterpenoids from A. amatymbica and evaluating their biological activities based on the ethnomedicinal information, was the primary focus of this investigation. Five bioassay guided isolated compounds: ent-13-hydroxy-16-kauren-19-oic acid (1), 16-hydroxy-kaur-6-en-19-oic acid (2), 14- acetoxy ent- kaur-16-en-19-oic acid (3), 14-oxokaur-16-en-19-oic acid (4), and 14-acetoxo-12-oxokaur-16-en-19-oic acid (5) were screened in vitro for their anti-inflammatory, cytotoxicity, and antimicrobial. The compounds were purify using open column chromatography, PTLC, and characterised with FTIR, NMR, and HRMS EI. The diterpenoids did not show cytotoxicity on the normal cell but showed a significant effect of cancer cell lines. 14-acetoxo-12-oxokaur-16-en-19-oic acid showed a high inhibitory effect on lipoxygenase with an EC50 of 19.10 ± 3.15 µg/ml compared to standard indomethacin with EC50 of 17.22 ± 5.48 µg/ml. Among the diterpenes tested, only 14-oxokaur-16-en-19-oic acid and 14-acetoxo-12-oxokaur-16-en-19-oic acid showed significant antibiotic activities against bacteria (MIC 125 µg/ml). Consequently, the antibiotic activity is structurally linked to the positions of acetate and oxo groups at C-14 and C-12 which enhances the activity of the diterpenoids. In vitro, biological activities result illustrated that the compounds can be a source of treatment and management for inflammation-related diseases with no cytotoxic effect. Therefore, justifying its traditional applications

Biography:

Thomas Werner is the chairman of the executive board of m4 Personalisierte Medizin .e.V., a charitable organization to further personalized medicine. He is also an adjunct professor at the Internal Medicine, Nephrology, University of Michigan in Ann Arbor, MI, USA. He received his PhD in 1986 and has authored more than 150 peer reviewed scientific articles and book chapters. He founded Genomatix Software GmbH in Munich 1997 and was the CEO and CSO of the company for more than 10 years. His research focus is on new approaches in translational and P4-medicine

Abstract:

Preventive, predictive, personalized, and participatory medicine (P4-medicine) requires science, medicine, judicial, ethics, and the general public, including politics to cooperate. Only broad consent and support will allow making the necessary changes to our existing health care system. This will not only ensure better medical treatment for many of us, but also offers unique opportunities to combine improved health care with economic saving, mostly coming from the first part - preventive medicine. Challenges are the acquisition of large amounts of molecular data (genome sequences, tumor genomes, transcriptomes, and an ever growing amount of biomarkers) from patients and also from the healthy population. Once sufficient data are available, suitable consent forms must accompany them in order to allow comparative analysis on a sufficiently large scale. Especially the interpretation of -omics data still presents formidable problems we need to overcome, as will be illustrated in just one example. Results need to be stored and safeguarded properly in order to fulfill legal and ethical requirements of data protection. However, current limitations are often decades old and entirely oblivious of the requirements and possibilities of P4-medicine. Here we need sufficient general education to ensure that politician can remove some obstacles in tune with their electorate. This includes health care providers who often see P4-medicine just as another huge attack on their budgets. They need to realize the saving potential especially in prevention and early treatment of chronic diseases. We need viable economic models to demonstrate these effects as real. I will summarize what our association is doing in detail to help facilitate to required change of mind sets in order to make P4-medicine a reality for all of us